Pharma News

Stanford University begins a clinical trial testing Sonire Therapeutics' focused ultrasound system, SUNRISE-II, for unresectable pancreatic cancer treatment.

University of Notre Dame researchers empirically compare CPZ and LPC preclinical models to study myelin loss and regeneration in multiple sclerosis.

The FDA approved the all-oral combination of Inqovi and Venclexta for newly diagnosed acute myeloid leukemia in adults 75 or older or chemo-ineligible.

GSK enters a new 3-year partnership with Protas to improve the quality, speed, and efficiency of late-stage clinical trials across core therapeutic areas.

Regeneron partners with Parabilis Medicines in a $2.3 billion deal to develop antibody-Helicon conjugates, a novel class of precision targeted therapies.

Harbour BioMed publishes preclinical data on LET003, an ACVR2A/2B antibody, showing promise as a rival to Eli Lilly's bimagrumab in obesity treatment.

New research reveals tuberculosis costs the world $1.35 trillion annually, draining 0.8% of global economic potential and heavily impacting poorer nations.

Apnimed receives FDA Fast Track designation for AD109, a first-in-class oral pharmacologic candidate designed to treat obstructive sleep apnea at night.

A new clinical trial evaluates whether a single mesenchymal stem cell infusion combined with standard therapies can stabilize early Alzheimer's disease.

Experts emphasize the vital role of preclinical in vitro and animal models in establishing antibiotic PK/PD targets and the need to consider host factors.

Onco-Innovations shares jump 79% as the micro-cap biotech secures AI collaborations with AstraZeneca and GSK and advances its PNKP inhibitor to trials.

Experts fact-check viral conspiracy theories claiming the recent Hantavirus outbreak is a planned pandemic, bioweapon, or COVID-19 vaccine side effect.